Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice

Lee, Ming Hsun; Roussel, Yvonne; Wilks, Mark; Tabaqchali, Soad

doi:10.1016/s0264-410x(01)00119-0

Cited by 88 publications

(58 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, little information is known about the effects of genetic variation of the enzyme subunits or its expression level on its catalytic activity. It is recognized that the active site of the enzyme is located in the B subunit that is involved in restoration of urease activity, induction Th17 cell response, induction of NF-κB and interleukin-8 production (Lee et al, 2001;Eaton et al, 2002;Beswick et al, 2006;Zhang et al, 2011). The aim of this study was to determine the relationships among ureB sequence diversity, urease activity of the collected strains and virulence property of H. pylori strains in patients with different histopathological changes.…”

Section: Introductionmentioning

confidence: 99%

Relationship between ureB Sequence Diversity, Urease Activity and Genotypic Variations of Different Helicobacter pylori Strains in Patients with Gastric Disorders

Ghalehnoei

Ahmadzadeh

Farzi

et al. 2016

Polish Journal of Microbiology

View full text Add to dashboard Cite

A b s t r a c tAssociation of the severity of Helicobacter pylori induced diseases with virulence entity of the colonized strains was proven in some studies. Urease has been demonstrated as a potent virulence factor for H. pylori. The main aim of this study was investigation of the relationships of ureB sequence diversity, urease activity and virulence genotypes of different H. pylori strains with histopathological changes of gastric tissue in infected patients suffering from different gastric disorders. Analysis of the virulence genotypes in the isolated strains indicated significant associations between the presence of severe active gastritis and cagA + (P = 0.039) or cagA/iceA1 genotypes (P = 0.026), and intestinal metaplasia and vacA m1 (P = 0.008) or vacA s1/m2 (P = 0.001) genotypes. Our results showed a 2.4-fold increased risk of peptic ulcer (95% CI: 0.483-11.93), compared with gastritis, in the infected patients who had dupA positive strains; however this association was not statistically significant. The results of urease activity showed a significant mean difference between the isolated strains from patients with PUD and NUD (P = 0.034). This activity was relatively higher among patients with intestinal metaplasia. Also a significant association was found between the lack of cagA and increased urease activity among the isolated strains (P = 0.036). While the greatest sequence variation of ureB was detected in a strain from a patient with intestinal metaplasia, the sole determined amino acid change in UreB sequence (Ala201Thr, 30%), showed no influence on urease activity. In conclusion, the supposed role of H. pylori urease to form peptic ulcer and advancing of intestinal metaplasia was postulated in this study. Higher urease activity in the colonizing H. pylori strains that present specific virulence factors was indicated as a risk factor for promotion of histopathological changes of gastric tissue that advance gastric malignancy. K e y w o r d s: Helicobacter pylori, virulence, factor urease activity, histopathological changes

show abstract

Section: Introductionmentioning

confidence: 99%

Relationship between ureB Sequence Diversity, Urease Activity and Genotypic Variations of Different Helicobacter pylori Strains in Patients with Gastric Disorders

Ghalehnoei

Ahmadzadeh

Farzi

et al. 2016

Polish Journal of Microbiology

View full text Add to dashboard Cite

show abstract

“…The only approved mucosal vaccines are pathogens (49), some of which may pose a risk of infection, particularly to children or immunocompromised individuals (36,39,46). Therefore, recent efforts to develop mucosal vaccine delivery systems have included ones that are not pathogenic, such as liposomes or microparticles (10,50), commensal bacteria (19,20,32,34,39,45,46), or noninvasive, noncommensal bacteria (11,18,31,42).…”

Section: Discussionmentioning

confidence: 99%

“…It is generally recognized as safe by the U.S. Food and Drug Administration. Many heterologous proteins have been expressed in L. lactis (11,12,18,23,31,42,53), and immunization with these strains elicits immune responses specific to heterologous antigens (43,52,55). However, we are aware of only one report (55) that shows that mucosal immunization with a lactococcal vaccine can reduce infection.…”

mentioning

confidence: 99%

Mucosal Vaccine Made from Live, RecombinantLactococcus lactisProtects Mice against Pharyngeal Infection withStreptococcus pyogenes

2004

View full text Add to dashboard Cite

A novel vaccine (LL-CRR) made from live, nonpathogenic Lactococcus lactis that expresses the conserved C-repeat region (CRR) of M protein from Streptococcus pyogenes serotype 6 was tested in mice. Nasally vaccinated mice produced CRR-specific salivary immunoglobulin A (IgA) and serum IgG. Subcutaneously vaccinated mice produced CRR-specific serum IgG but not salivary IgA. A combined regimen produced responses similar to the salivary IgA of nasally vaccinated mice and serum IgG of subcutaneously vaccinated mice. Mice vaccinated nasally or with the combined regimen were significantly protected against pharyngeal infection following a nasal challenge with S. pyogenes M serotype 14. Mice vaccinated subcutaneously were not protected against pharyngeal infection. Mice in all three LL-CRR vaccination groups were significantly protected against the lethal effects of S. pyogenes. Only 1 of 77 challenged mice that were vaccinated with LL-CRR died, whereas 60 of 118 challenged mice that were vaccinated with a control strain or phosphatebuffered saline died. In conclusion, mucosal vaccination with LL-CRR produced CRR-specific salivary IgA and serum IgG, prevented pharyngeal infection with S. pyogenes, and promoted survival.

show abstract

“…High potential of E7 antigen and interleukin-12 secreting lactococci strains as mucosal vaccine have been observed advantageous in future for prophylactic and therapeutic uses by inducing systemic and mucosal immune responses in mice against human papilloma-virus type 16-induced tumors (Bermúdez-Humarán et al, 2008). It has been reported to be used as a vaccine delivery system against Helicobacter (H.) pylori infection in mice by expressing H. pylori urease subunit B gene in L. lactis (Lee et al, 2001). It has been made live vaccine against brucellosis by targeting and producing Brucella abortus antigen L7/L12 in L. lactis (Ribeiro et al, 2002).…”

Section: Therapeutic Rolesmentioning

confidence: 99%

Probiotic Lactococcus lactis: A Review

Khemariya

Singh

Nath

et al. 2017

Turkish JAF Sci.Tech.

View full text Add to dashboard Cite

Lactococcus lactis plays a critical role in food, dairy and health sectors. In food and dairy industries, it is found in production processes of various fermented products such as sausages, pickled vegetables, beverages such as beer and wine, breads, soymilk kefir, sour milk, butter, cream, fresh cheese and different types of cheeses, like Cheddar, Colby, Cottage cheese, Camembert, cream cheese, Roquefort and Brie. Additionally, there is an increasing interest towards the possible health benefits of the probiotic activity of this organism which generally is species and strain specific and depends upon the survival in gastrointestinal tract with sufficient number. Certain strains have the ability to produce antimicrobial peptide called nisin which exhibits preservative potential. Therefore, application of bacteriocinogenic Lactococcus lactis in food and dairy sectors to preserve foods as a natural way and contributing health promoting attributes due to probiotic activity would definitely fulfil today's consumer demands. This paper aimed to review the adaptation, antibiotic resistance, therapeutic and preservation potential of bacteriocinogenic and probiotic Lactococcus lactis.

show abstract

Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice

Cited by 88 publications

References 28 publications

Relationship between ureB Sequence Diversity, Urease Activity and Genotypic Variations of Different Helicobacter pylori Strains in Patients with Gastric Disorders

Relationship between ureB Sequence Diversity, Urease Activity and Genotypic Variations of Different Helicobacter pylori Strains in Patients with Gastric Disorders

Mucosal Vaccine Made from Live, RecombinantLactococcus lactisProtects Mice against Pharyngeal Infection withStreptococcus pyogenes

Probiotic Lactococcus lactis: A Review

Contact Info

Product

Resources

About